Chief Financial Officer and principal financial officer · Avalo Therapeutics, Inc. (AVTX)

Christopher Sullivan

A named executive officer of Avalo Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,929,534

Salary $400,000Stock awards $712,288

FY2023: $607,645

4th of 4 named executive officers at Avalo Therapeutics by FY2024 total.

4 named officers on file for Avalo Therapeutics, FY2024

Christopher Sullivan’s pay file — $29

  • 3 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Avalo Therapeutics’s whole pay program stands against its peers

  • Avalo Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AVTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 1, 2025 (DEF 14A).

Free

Get Christopher Sullivan’s full pay file as a PDF — free

More than this page: up to 10 years of Christopher’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Christopher Sullivan compensation by year

Avalo Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Avalo Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024
Salary$344,135$350,000$400,000
Bonus$0$0$0
Stock awards$0$0$712,288
Option awards$301,614$173,645$1,587,846
Non-equity incentive$72,800$84,000$229,400
Pension and deferred compensation$0$0$0
All other$50,000$0$0
Total$768,549$607,645$2,929,534

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Avalo Therapeutics, Inc. DEF 14A filed May 1, 2025, accession 0001628280-25-021311, and prior-year filings.

How this page was built: the Avalo Therapeutics, Inc. filed document, accession 0001628280-25-021311. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2025.

$769K
$608K
$2.9M
FY22
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option89—$715.20
Option186,700—$9.88
RSU72,600——
Option44—$2016.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Avalo Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Avalo Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Garry NeilChief Executive Officer, President and principal executive officer$7,212,749
Mittle DoyleChief Medical Officer$3,033,757
Mittie FACRChief Medical Officer$3,033,757
Christopher Sullivan · this pageChief Financial Officer and principal financial officer$2,929,534

The full Avalo Therapeutics compensation record

free company brief

This page is one person within Avalo Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Avalo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Christopher Sullivan's compensation dossier · One-time report. No refunds.